ClinicalTrials.gg
CompletedNCT02114385Updated Nov 1, 2018Results posted

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

A Phase 3 interventional study of V503 and GARDASIL in Papilloma Viral Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 7 sites in 3 countries. Open to participants aged 16 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-01.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
16 Years to 26 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Enrollment
17th of 31
500 · median 700
Started
2014
with 1 other
Phase 3
16 of 31
2 open now
Registered
5th of 31
by date
Lead sponsor
15 of 31
Merck Sharp & Dohme LLC

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 17th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 5th registered.

Papillomavirus Infections

580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 16 Years to 26 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

Primary objective

To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men

Read the detailed description

Secondary objectives

  • To evaluate the tolerability of V503 in 16- to 26-year-old men.
  • To summarise humoral immune responses, including anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 GMTs and seroconversion rates at 4 weeks post-dose 3, in 16- to 26-year-old men who received V503 or GARDASIL
03

Conditions studied

  • Papilloma Viral Infection

Keywords

  • Prevention
04

Who can participate

Ages eligible
16 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a man, between the ages of 16 years and 0 days and 26 years and 364 days on the day of enrolment.
  • Subject is a man who has had no more than 5 lifetime female sexual partners.
  • Subject is judged to be in good physical health on the basis of medical history, physical examination, and laboratory results.
  • Subject, or subject's parent or guardian, fully understand study procedures, alternative treatments available, the risks involved with the study, and voluntarily agree to participate by giving written .

Exclusion criteria

Exclusion Criteria:

  • Subject who has had sex with a male partner.
  • Subject has a history of HPV-related external genital lesions or HPV-related anal lesions
  • Subject has a known allergy to any vaccine component, including aluminium, yeast, or BENZONASE
  • Subject has a history of severe allergic reaction that required medical intervention.
  • Subject has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
  • Subject is concurrently enrolled in clinical studies of medicinal products.
  • Subject has donated blood within 1 week prior to the Day 1 vaccination, or intends to donate during Day 1 through Month 7 of the study.
  • Subject is currently or has been diagnosed as having a congenital or acquired immunodeficiency, infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other condition.
  • Subject has had a splenectomy.
  • Subject is receiving or has received in the year prior to enrolment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide, TNF-α antagonists, monoclonal antibody therapies, intravenous gamma globulin, antilymphocyte sera, or other therapy known to interfere with the immune response.
  • Subject has received any immune globulin product or blood-derived product within the 6 months prior to the Day 1 vaccination, or plans to receive any such product during Day 1 through Month 7 of the study.
  • Subject has received non-replicating (inactivated) vaccines within 14 days prior to the Day 1 vaccination or has received replicating (live) vaccines within 21 days prior to the Day 1 vaccination.
  • Subject has received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo.
  • Subject has had a fever within the 24-hour period prior to the Day 1 vaccination.
  • Subject has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
  • Subject is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
  • Subject is, at the time of signing , a user of recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
  • Subject, or subject's parent or guardian, is or has an immediate family member (spouse or children) who is investigational site or sponsor staff directly involved with this trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    V503

    9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6

    Biological: V503

  • Active comparator
    GARDASIL

    Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6

    Biological: GARDASIL

Interventions

  • BiologicalV503

    9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection

    Also known as: 9vHPV vaccine

  • BiologicalGARDASIL

    Quadrivalent HPV \[Types 6, 11, 16, and 18\] L1 virus-like particle vaccine, 0.5-mL intramuscular injection

    Also known as: qHPV vaccine

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18

    Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.

    Time frame: 4 weeks postdose 3 (Month 7)

Secondary outcomes

  1. GMTs to HPV Types 31/33/45/52/58

    Serum antibodies to HPV types 31, 33, 45, 52, and 58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.

    Time frame: 4 weeks postdose 3 (Month 7)

  2. Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58

    Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Type 33: ≥8; HPV Type 45: ≥8; HPV Type 52: ≥8; HPV Type 58: ≥8.

    Time frame: 4 weeks postdose 3 (Month 7)

  3. Percentage of Participants With One or More Adverse Events

    The percentage of participants with one or more adverse events was assessed.

    Time frame: Up to 15 days after any vaccination

  4. Percentage of Participants With Study Discontinuation Due to an Adverse Event

    The percentage of participants discontinued from the study due to an adverse event was assessed.

    Time frame: Up to Month 7

  5. Percentage of Participants With One or More Injection-site Adverse Reactions

    The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.

    Time frame: Up to 5 days after any vaccination

  6. Percentage of Participants With Maximum Temperature ≥37.8 °C

    The percentage of participants with a maximum temperature ≥37.8 °C was assessed.

    Time frame: Up to 5 days after any vaccination

  7. Percentage of Participants With One or More Systemic Adverse Events

    The percentage of participants with one or more systemic adverse events was assessed.

    Time frame: Up to 15 days after any vaccination

  8. Percentage of Participants With One or More Serious Adverse Events

    The percentage of participants with one or more serious adverse events was assessed.

    Time frame: Up to 15 days after any vaccination

07

Results

Posted Nov 1, 2018

Participant flow

A total of 502 participants were screened and 500 were randomized

Participant flow — Overall Study
MilestoneV503GARDASIL
Started249251
Vaccinated249251
Completed246243
Not completed38
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up06

Outcome measures

PrimaryGeometric Mean Titers (GMTs) to HPV Types 6/11/16/18

Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Geometric mean · milli Merck U/mL
Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18
milli Merck U/mLV503GARDASIL
HPV Type 6758.3 (665.9 to 863.4)618.4 (554.0 to 690.3)
HPV Type 11681.7 (608.9 to 763.4)769.1 (683.5 to 865.3)
HPV Type 163924.1 (3513.8 to 4382.3)3787.9 (3378.4 to 4247.0)
HPV Type 18884.3 (766.4 to 1020.4)790.9 (683.0 to 915.7)
Statistical analysis
  • V503 vs GARDASIL · ANOVA · p = <0.001 · Gmt ratio: 1.23 · 95% CI 1.04 to 1.45GMT ratio = GMT (V503) / GMT (Gardasil)
  • V503 vs GARDASIL · ANOVA · p = <0.001 · Gmt ratio: 0.89 · 95% CI 0.76 to 1.04GMT ratio = GMT (V503) / GMT (Gardasil)
  • V503 vs GARDASIL · ANOVA · p = <0.001 · Gmt ratio: 1.04 · 95% CI 0.89 to 1.21GMT ratio = GMT (V503) / GMT (Gardasil)
  • V503 vs GARDASIL · ANOVA · p = <0.001 · Gmt ratio: 1.12 · 95% CI 0.91 to 1.37GMT ratio = GMT (V503) / GMT (Gardasil)
SecondaryGMTs to HPV Types 31/33/45/52/58

Serum antibodies to HPV types 31, 33, 45, 52, and 58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Geometric mean · milli Merck U/mL
GMTs to HPV Types 31/33/45/52/58
milli Merck U/mLV503GARDASIL
HPV Type 31794.4 (694.2 to 909.2)14.8 (12.5 to 17.5)
HPV Type 33460.5 (410.6 to 516.4)3.4 (3.1 to 3.7)
HPV Type 45262.9 (226.2 to 305.5)2.5 (2.3 to 2.8)
HPV Type 52430.7 (377.8 to 491.0)1.9 (1.8 to 2.1)
HPV Type 58691.0 (614.9 to 776.5)5.7 (5.0 to 6.5)
SecondaryPercentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58

Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Type 33: ≥8; HPV Type 45: ≥8; HPV Type 52: ≥8; HPV Type 58: ≥8.

Time frame:
4 weeks postdose 3 (Month 7)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58
Percentage of participantsV503GARDASIL
HPV Type 698.2 (95.6 to 99.5)98.7 (96.2 to 99.7)
HPV Type 11100 (98.4 to 100)100 (98.4 to 100)
HPV Type 16100 (98.4 to 100)100 (98.5 to 100)
HPV Type 1899.6 (97.6 to 100)99.6 (97.7 to 100)
HPV Type 31100 (98.4 to 100)61.6 (55.1 to 67.8)
HPV Type 33100 (98.4 to 100)16.9 (12.4 to 22.4)
HPV Type 45100 (98.4 to 100)9.3 (5.9 to 13.8)
HPV Type 52100 (98.4 to 100)2.5 (0.9 to 5.5)
HPV Type 58100 (98.4 to 100)36.1 (29.9 to 42.6)
SecondaryPercentage of Participants With One or More Adverse Events

The percentage of participants with one or more adverse events was assessed.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Adverse Events
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Adverse Events82.3 (76.9 to 86.8)81.9 (76.5 to 86.4)
SecondaryPercentage of Participants With Study Discontinuation Due to an Adverse Event

The percentage of participants discontinued from the study due to an adverse event was assessed.

Time frame:
Up to Month 7
Reported as:
Number · Percentage of participants
Percentage of Participants With Study Discontinuation Due to an Adverse Event
Percentage of participantsV503GARDASIL
Percentage of Participants With Study Discontinuation Due to an Adverse Event0 (0 to 1.5)0 (0 to 1.5)
SecondaryPercentage of Participants With One or More Injection-site Adverse Reactions

The percentage of participants with one or more injection-site adverse reactions (solicited or unsolicited) was assessed.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Injection-site Adverse Reactions
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Injection-site Adverse Reactions79.0 (73.4 to 83.9)72.2 (66.2 to 77.7)
SecondaryPercentage of Participants With Maximum Temperature ≥37.8 °C

The percentage of participants with a maximum temperature ≥37.8 °C was assessed.

Time frame:
Up to 5 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Maximum Temperature ≥37.8 °C
Percentage of participantsV503GARDASIL
Percentage of Participants With Maximum Temperature ≥37.8 °C2.82.4
SecondaryPercentage of Participants With One or More Systemic Adverse Events

The percentage of participants with one or more systemic adverse events was assessed.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Systemic Adverse Events
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Systemic Adverse Events40.7 (34.6 to 47.1)40.3 (34.2 to 46.7)
SecondaryPercentage of Participants With One or More Serious Adverse Events

The percentage of participants with one or more serious adverse events was assessed.

Time frame:
Up to 15 days after any vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With One or More Serious Adverse Events
Percentage of participantsV503GARDASIL
Percentage of Participants With One or More Serious Adverse Events0.0 (0.0 to 1.5)0.0 (0.0 to 1.5)

Adverse events

Collected over All adverse events: up to 15 days after each vaccination; serious adverse events: up to Month 7. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V503—0/248 (0%)196/248 (79%)
GARDASIL—6/248 (2.4%)189/248 (76.2%)
Most frequent serious events
Most frequent serious events
EventV503GARDASIL
Cytomegalovirus infectionInfections and infestations0/2481/248
ConcussionInjury, poisoning and procedural complications0/2481/248
Foot fractureInjury, poisoning and procedural complications0/2481/248
Joint dislocationInjury, poisoning and procedural complications0/2481/248
Ligament injuryInjury, poisoning and procedural complications0/2481/248
Ligament ruptureInjury, poisoning and procedural complications0/2481/248
Most frequent other events
Most frequent other events
EventV503GARDASIL
Injection-site painGeneral disorders193/248174/248
Injection-site erythemaGeneral disorders38/24843/248
HeadacheNervous system disorders29/24837/248
Injection-site swellingGeneral disorders36/24823/248
NasopharyngitisInfections and infestations11/24814/248

Baseline characteristics

Randomized participants

Age, Continuous
Age, Continuous(Years)V503GARDASILTotal
Mean20.8 ± 2.721.3 ± 3.021.0 ± 2.8
Age, Customized
Age, Customized(Participants)V503GARDASILTotal
<18 years old373875
>=18 years old212213425
Sex: Female, Male
Sex: Female, Male(Participants)V503GARDASILTotal
Female000
Male249251500
08

Study locations

7 sites
  • Sanofi Pasteur MSD Investigational Site 1002
    Ghent, Belgium
  • Sanofi Pasteur MSD Investigational Site 1003
    Leuven, Belgium
  • Sanofi Pasteur MSD Investigational Site 1001
    Wilrijk, Belgium
  • Sanofi Pasteur MSD Investigational Site 3001
    Mainz, Germany
  • Sanofi Pasteur MSD Investigational Site 4001
    Amsterdam, Netherlands
  • Sanofi Pasteur MSD Investigational Site 4003
    Amsterdam, Netherlands
  • Sanofi Pasteur MSD Investigational Site 4002
    Nijmegen, Netherlands
09

References and documents

Publications

  • Van Damme P, Meijer CJLM, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016 Jul 29;34(35):4205-4212. doi: 10.1016/j.vaccine.2016.06.056. Epub 2016 Jun 25. PubMed 27354258 ↗
  • Moreira ED, Giuliano AR, de Hoon J, Iversen OE, Joura EA, Restrepo J, Van Damme P, Vandermeulen C, Ellison MC, Krick A, Shields C, Heiles B, Luxembourg A. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age. Hum Vaccin Immunother. 2018 Feb 1;14(2):396-403. doi: 10.1080/21645515.2017.1403700. Epub 2017 Dec 14. PubMed 29211620 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2014
First posted
Apr 15, 2014
Start
Mar 24, 2014
Primary completionActual
Apr 22, 2015
CompletionActual
Apr 22, 2015
Results first posted
Nov 1, 2018
Last update
Nov 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02114385
Responsible party
Sponsor
First posted
Apr 15, 2014
Start date
Mar 24, 2014
Primary completion
Apr 22, 2015
Completion
Apr 22, 2015
Results posted
Nov 1, 2018
Last update
Nov 1, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion